EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies

▴ HighTide Therapeutics
Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801).

HONG KONG, Sept 11, 2024 - (ACN Newswire) - HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, presents at the 60th European Association for the Study of Diabetes (EASD) Annual Meeting, taking place from September 10-13, 2024 in Madrid, Spain. The presentations include post-hoc analyses of two Phase 2 clinical studies of berberine ursodeoxycholate (HTD1801), a gut-liver anti-inflammatory metabolic modulator, in patients with type 2 diabetes mellitus (T2DM).

“These data provide additional insight on the potential benefits of HTD1801, a novel, multifunctional therapy being developed for the treatment of patients with T2DM. The two ongoing Phase 3 studies (NCT06350890, NCT06415773), fully enrolled in 2Q 2024, evaluate the efficacy and safety of HTD1801 in T2DM patients (as monotherapy or in combination with metformin). We look forward to the results of these Phase 3 studies which we expect to announce in 2025,” said Dr. Leigh MacConell, Chief Development Officer of HighTide.

“Efficacy of Berberine Ursodeoxycholate (HTD1801) in Chinese and Western Patients with T2DM”

(Presentation 711, Oral Presentation, September 11, 12:45 PM CEST)

About the Abstract: T2DM and MASH are highly interrelated, the presence of each increasing risk of outcomes. Patients with both T2DM and MASH are at higher risk of histologic progression in MASH, cardiovascular outcomes, hepatic outcomes, and all-cause mortality. The purpose of this analysis was to compare the effects of HTD1801 in Chinese and Western patients with T2DM with or without MASH. These data demonstrate that while the two populations are ethnically distinct with related but different diseases, treatment with HTD1801 was associated with improvements in key measures of glycemic, cardiometabolic, and hepatic benefit in both populations. HTD1801 offers holistic benefits that are observed in both Chinese and Western patients, irrespective of underlying disease, that address core aspects of both T2DM and MASH.

“Berberine Ursodeoxycholate (HTD1801) Provides a Unique Therapeutic Approach for Patients with Metabolic Diseases and Severe Insulin Resistance”

(Presentation 708, Oral Presentation, September 11, 12:45 PM CEST)

About the Abstract: Insulin resistance is a significant risk factor for T2DM, obesity and MASH. HTD1801 enhances the utilization of glucose and fats through activation of AMP-activated protein kinase (AMPK), thereby improving insulin sensitivity. As HTD1801 is under development as a treatment for patients with T2DM, as well as MASH, we analyzed the effects of HTD1801 response based on degree of insulin resistance. These data demonstrate that HTD1801 can alleviate the metabolic inhibitory effects caused by hyperinsulinemia, leading to even greater hepatic and metabolic benefits in patients with more severe insulin resistance, offering a unique therapeutic approach for individuals with T2DM and/or MASH.

About HighTide Therapeutics

HighTide Therapeutics, Inc. (2511.HK) is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional multi-targeted therapies with chronic liver and metabolic diseases with significant unmet medical needs. The company is developing multiple clinical assets, including therapy for metabolic dysfunction-associated steatohepatitis (MASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC). Berberine ursodeoxycholate (HTD1801), the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC. In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Could Your Irregular Heartbeat Be Reversible? How New Research is Redefining Atrial Fibrillation CareOctober 09, 2024
Defying the Odds: The Innovative Treatment Prolonging Life in Advanced Breast CancerOctober 09, 2024
Medanta Doctors Recognised in Stanford University's Global Rankings of Top 2% ScientistsOctober 09, 2024
Vector-Borne Diseases in India: 2024 OverviewOctober 09, 2024
What Makes The Mind Hear Voices: The Truth Behind Hearing Voices in SchizophreniaOctober 08, 2024
Preventing Pregnancy Complications: Why a Healthy Weight Before Conception MattersOctober 08, 2024
Are Your Favorite Beverages Putting You at Risk of Stroke? Here’s What the Latest Research SaysOctober 08, 2024
Sharp Sight Eye Hospitals Emphasizes Importance of Regular Eye Checkups with New Campaign Featuring Shishir SharmaOctober 08, 2024
Microplastics in Bloodstream: The Hidden Link to Cardiovascular and Neurological DisordersOctober 08, 2024
India Joins International Medical Device Regulators Forum: A Leap Toward Global Health CollaborationOctober 05, 2024
The Science of Overeating: Why You Can’t Stop at Just One BiteOctober 05, 2024
The Toxic Truth: How Alcohol Fuels Six Deadly CancersOctober 05, 2024
Lenacapavir: India’s Pharmaceutical Giants to Produce a Twice-a-Year Pill Poised to Rewrite HIV PreventionOctober 04, 2024
Can Ending Smoking by 2050 Really Save 1.2 Million Lives? New Lancet Study RevealsOctober 04, 2024
Colon Cancer Crisis: Why It’s Attacking Younger GenerationsOctober 04, 2024
Eye Health Program for Low-Income Residents Launched in Hingoli, MaharashtraOctober 04, 2024
Are we on the path to end AIDS by 2030?October 03, 2024
TTK Prestige Announces Shubhutsav- A Special Festive Offer, Elevating Home CookingOctober 03, 2024
Tata Soulfull Launches Tata Soulfull Corn Flakes+, With the Goodness of Millets in Every Flake October 03, 2024
The Bitter Truth Behind Sweet Treats: Hidden Cancer Risks in Your Favorite CakesOctober 03, 2024